PT - JOURNAL ARTICLE AU - Bychkov, Gleb AU - Bang, Benedicte AU - Engsner, Niklas AU - Heyman, Mats AU - Nordenvall, Anna Skarin AU - Tettamanti, Giorgio AU - Ponten, Emeli AU - Albert, Jan AU - Jörnsten, Rebecka AU - Strannegård, Claes AU - Nordgren, Ann TI - Evidence of seasonal variation of childhood acute lymphoblastic leukemia in Sweden AID - 10.1101/2023.02.12.23285595 DP - 2023 Jan 01 TA - medRxiv PG - 2023.02.12.23285595 4099 - http://medrxiv.org/content/early/2023/02/12/2023.02.12.23285595.short 4100 - http://medrxiv.org/content/early/2023/02/12/2023.02.12.23285595.full AB - Background Recent molecular studies of B-cell precursor acute lymphoblastic leukemia (BCP-ALL) have started to delineate the nature and timing of genetic variants and those responsible for subsequent progression to overt leukemia. However, the etiology behind both initiation and progression remains largely unknown. Nonetheless, theories, but also epidemiological evidence, of how exposure to common infections and other microbes in our environment modulates the risk of developing childhood BCP-ALL, have emerged. In light of these theories and the well-known phenomena of seasonality in infectious disease spread, childhood ALL has been analyzed for signs of seasonal variation, with differing results.Methods In this study we applied the Bayesian Generalized Auto Regressive Integrated Moving Average with external variables (GARIMAX) model, adapted for count data via a negative binomial distribution, to study seasonal variation of incidence in a Swedish population-based cohort of 1601 BCP-ALL cases. The studied cases were aged 0-18 years at diagnosis and identified from the Swedish Childhood Cancer Registry (SCCR). Also, two subgroups of BCP-ALL represented by the most abundant genetic subtypes, ETV6/RUNX1 and HeH respectively, were analyzed accordingly. All analyses were performed in two stages. The first stage identified the presence of the repeatable pattern using harmonic functions, and the second stage consisted of the identification of the peak months in the series.Results An informative seasonal variation in BCP-ALL incidence numbers, displaying a peak in August and September, was detected in the total cohort of 1601 individuals. No seasonality was detected analyzing the subtype groups HeH and ETV6/RUNX1 positive BCP-ALL, respectively.Conclusion The manifested seasonality in BCP-ALL with a peak in August-September may suggest that the prolonged period of minimal viral spread during Swedish summer vacation causes a temporary halt in the last step of progression to overt disease and consequently an accumulated number of cases presenting in August-September.Competing Interest StatementThe authors have declared no competing interest.Funding StatementThis study was supported by grants from the Swedish Childhood Cancer Fund, the Swedish Cancer Society, the Cancer Society of Stockholm, the Swedish Research Council, the Stockholm Regional Council, Mary Beves Stiftelse for Barncancerforskning, the Swedish Rare Diseases Research foundation, Berth von Kantzow's foundation, Karolinska Institutet Research Foundation, Hallsten Research foundation, Stiftelsen Frimurare Barnhuset in Stockholm and the Stockholm County Council. Funders had no role in study design, data collection and analysis, decision to publish, or preparation of the manuscript.Author DeclarationsI confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.YesThe details of the IRB/oversight body that provided approval or exemption for the research described are given below:Regional Ethical Review Board in Stockholm, Sweden 564 (ethics permit numbers 2018/1849-32I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.YesI understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).YesI have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.YesAll data produced in the present study are available upon reasonable request to the authors